Bio-Techne is set to report its first-quarter fiscal 2027 earnings on Tuesday, marking what could be one of its last updates as an independent company before its acquisition by Merck closes by late 2026 or early 2027. Analysts anticipate earnings of $0.45 per share on revenue of $293 million, both representing sequential declines from the prior quarter’s $0.52 per share and $321.2 million.
Wall Street has adopted a cautious stance ahead of the report, with the stock holding a neutral consensus rating from 13 analysts. The mean price target of $70.50 suggests roughly 3% downside from Bio-Techne’s current price of $72.66, which is just below its 52-week high of $72.75. Argus recently downgraded Bio-Techne from buy to sell, reflecting growing skepticism about the company’s near-term fundamentals.
Investors are closely watching for signs of seasonal softness or deeper demand headwinds in Bio-Techne’s core markets, which include academic, biopharmaceutical, and clinical customers. The company has faced tighter research budgets and more selective capital spending this year. Additionally, updates on the pending Merck acquisition and integration planning could influence the stock’s movement.
Bio-Techne’s positioning in the fast-growing cell therapy market is also under scrutiny. The company recently opened a new GMP manufacturing facility in Bristol, U.K., to expand production capacity for cell therapy applications. While near-term results may soften, this move signals confidence in long-term demand. In August, Bio-Techne met analyst expectations with $0.52 per share in earnings and slightly exceeded revenue forecasts with $321.2 million, a 2% beat.